产品
编 号：F170757
分子式：C21H21ClN4OS
分子量：412.94
分子式：C21H21ClN4OS
分子量：412.94
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 146939-27-7
产品详情
生物活性：
Ziprasidone (CP-88059), an orally active antipsychotic agent, is a combined 5-HT and dopamine receptor antagonist. Ziprasidone mesylate trihydrate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM).
体内研究：
Ziprasidone (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold.Animal Model:Eight-week-old female Sprague-Dawleyrats weighing 200 to 250 g
Dosage:20 mg/kg
Administration:Oral gavage; 20 mg/kg; once daily; 7 weeks
Result:Gained significantly less weight (P = 0.031), had a lower level of physical activity (P = 0.016), showed a higher resting energy expenditure (P < 0.001), and displayed a greater capacity for thermogenesis when subjected to cold (P < 0.001).
体外研究：
Ziprasidone (0-500 nM, 150 seconds) blocks wild-type hERG current.
Ziprasidone (CP-88059), an orally active antipsychotic agent, is a combined 5-HT and dopamine receptor antagonist. Ziprasidone mesylate trihydrate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM).
体内研究：
Ziprasidone (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold.Animal Model:Eight-week-old female Sprague-Dawleyrats weighing 200 to 250 g
Dosage:20 mg/kg
Administration:Oral gavage; 20 mg/kg; once daily; 7 weeks
Result:Gained significantly less weight (P = 0.031), had a lower level of physical activity (P = 0.016), showed a higher resting energy expenditure (P < 0.001), and displayed a greater capacity for thermogenesis when subjected to cold (P < 0.001).
体外研究：
Ziprasidone (0-500 nM, 150 seconds) blocks wild-type hERG current.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备